WeVote
Log In

Bill

Bill

PS 252

Para enmendar la Sección 4030.12 de la Ley 1-2011, según enmendada, conocida como el "Código de Rentas Internas para un Nuevo Puerto Rico", con el fin de eximir del pago de impuesto sobre ventas y uso (IVU) a los medicamentos sin receta comprados o despachados en un establecimiento autorizado a personas de sesenta y cinco (65) años o más.

2025-2028 Session

Bill would exempt seniors 65+ from Puerto Rico sales tax on over-the-counter medications, reducing government revenue during fiscal recovery period.

Comisión no recomienda aprobación de la medida
0
WeVote Research Nonpartisan
Bill Summary · PS 252

Legislative bill overview

Bill PS 252 proposes to amend Puerto Rico's Internal Revenue Code (Law 1-2011) by exempting over-the-counter medications from the sales and use tax (IVU) when purchased by individuals aged 65 and older. This would create a tax exemption specifically for seniors buying non-prescription drugs at authorized establishments.

Why is this important

Seniors often face higher medication costs due to increased healthcare needs, and this exemption could reduce out-of-pocket expenses for a vulnerable population. However, the tax exemption would decrease government revenue at a time when Puerto Rico faces ongoing fiscal challenges and debt obligations from its 2017 bankruptcy restructuring.

Potential points of contention

  • Revenue impact: The government revenue loss from exempting OTC medications for all seniors 65+ could be substantial and cumulative, affecting public services funding during Puerto Rico's fiscal recovery period
  • Implementation complexity: Distinguishing between eligible (over-the-counter) and ineligible medications at point-of-sale requires clear regulatory definitions and enforcement mechanisms
  • Equity concerns: The exemption benefits only seniors with access to authorized establishments and formal purchases; those buying from informal markets or having difficulty accessing pharmacies may not benefit equally
  • Why the commission rejected it: The Finance Committee's recommendation against approval (September 2025) suggests concerns about fiscal sustainability or implementation feasibility outweighed the benefit to seniors

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.